Last update 21 Nov 2024

AD-010

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Protein drugs

Synonyms

blood clotting regulatory protein(Jiangsu Aidea Pharmaceutical), coagulation regulatory protein(Jiangsu Aidea Pharmaceutical), natural thrombomodulin(Jiangsu Aidea Pharmaceutical)

+ [4]

Target

THBD

Mechanism

THBD stimulants(Thrombomodulin stimulants)

Therapeutic Areas

Hemic and Lymphatic DiseasesOther Diseases

Active Indication

Disseminated Intravascular CoagulationInflammation

Inactive Indication-

Originator Organization

Jiangsu Aidea Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Aidea Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Clinical Trials associated with AD-010

JPRN-UMIN000012590 / RecruitingNot ApplicableIIT

The retrospective study of treatment by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis, acute respiratory distress sydmrome - The treatment of thrombomodulin for acute respiratory failure

Start Date01 Apr 2010

Sponsor / Collaborator

Chiba University

100 Clinical Results associated with AD-010

100 Translational Medicine associated with AD-010

100 Patents (Medical) associated with AD-010

288

Literatures (Medical) associated with AD-010

16 Sep 2024·Future Medicinal Chemistry

Molecular docking, derivatization, characterization and biological assays of amantadine

Article

Author: Ahmad, Irshad ; Akram, Muhammad Toseef ; Awan, Breena ; Khan, Muhammad Rizwan ; Khan, Mohsin Abbas ; Ullah, Farhat ; Yasmeen, Zarmeena

Background: Derivatization has been tremendously utilized in the field of drug discovery for optimizing the pharmacological properties and improving safety, efficacy and selectivity.Methodology: Schiff's bases (AD1-AD11) are synthesized through amantadine condensation with different aldehydes and ketones. Fourier transform infrared, ¹H NMR, ¹³C NMR, TLC, liquid chromatography mass spectrometry analysis, in silico studies, molecular docking and antiviral activity through hemagglutinin test were performed for evaluation of new compounds.Results: AD2, 3 and 9-11 showed greater antiviral activity than the parent drug. Among all derivatives, AD2 and AD3 exhibited good potential against α-amylase while AD7 and AD10 showed stronger inhibition against α-glucosidase.Conclusion: So, it is concluded that the most potent derivatives can be used as lead compounds in novel drug design of antiviral antidiabetic agents.

28 Aug 2024·Cureus

Iliopsoas Abscess, Spondylodiscitis, Septic Pulmonary Embolism, and Symmetrical Peripheral Gangrene by Hypermucoviscous Klebsiella pneumoniae

Article

Author: Hayashi, Koji ; Hayashi, Maho ; Hamada, Hina ; Morikawa, Yukie ; Shirasaki, Akihisa ; Yamamoto, Chie

Hypermucoviscous Klebsiella pneumoniae (hmKP) is a bacterium known to cause lesions, including abscesses, in various organs. Unlike typical Klebsiella pneumoniae, hmKP can yield a positive string test in culture specimens. Infections caused by hmKP often become severe and are associated with a poor prognosis. In this report, we describe a case of iliopsoas abscess, spondylodiscitis, septic pulmonary embolism, and symmetrical peripheral gangrene (SPG) caused by hmKP. The patient received non-invasive positive-pressure ventilation, hemodialysis, platelet transfusions, fresh frozen plasma, thrombomodulin, and intensive antibiotic therapy including rifampicin. The patient underwent 148 days of antibiotic therapy and achieved a good outcome.

01 Jul 2024·International Journal of Neuropsychopharmacology

Thrombomodulin Improves Cognitive Deficits in Heat-Stressed Mice

Article

Author: Chang, Ching-Ping ; Wang, Lin-Yu ; Lin, Cheng-Hsien ; Tang, Ling-Yu

AbstractBackgroundThrombomodulin (TM) exerts anticoagulant and anti-inflammatory effects to improve the survival of patients with septic shock. Heat stroke resembles septic shock in many aspects. We tested whether TM would improve cognitive deficits and related causative factors in heat-stressed (HS) mice.MethodsAdult male mice were exposed to HS (33°C for 2 hours daily for 7 consecutive days) to induce cognitive deficits. Recombinant human soluble TM (1 mg/kg, i.p.) was administered immediately after the first HS trial and then once daily for 7 consecutive days. We performed the Y-maze, novel objective recognition, and passive avoidance tests to evaluate cognitive function. Plasma levels of lipopolysaccharide (LPS), high-mobility group box 1 (HMGB1), coagulation parameters, and both plasma and tissue levels of inflammatory and oxidative stress markers were biochemically measured. The duodenum and hippocampus sections were immunohistochemically stained. The intestinal and blood-brain barrier permeability were determined.ResultsCompared with controls, HS mice treated with TM had lesser extents of cognitive deficits, exacerbated stress reactions, gut barrier disruption, endotoxemia, blood-brain barrier disruption, and inflammatory, oxidative, and coagulatory injury to heart, duodenum, and hippocampal tissues, and increased plasma HMGB1. In addition to reducing cognitive deficits, TM therapy alleviated all the abovementioned complications in heat-stressed mice.ConclusionsThe findings suggest that HS can lead to exacerbated stress reactions, endotoxemia, gut barrier disruption, blood-brain barrier disruption, hippocampal inflammation, coagulopathy, and oxidative stress, which may act as causative factors for cognitive deficits. TM, an anti-inflammatory, antioxidant, and anti-coagulatory agent, inhibited heat stress-induced cognitive deficits in mice.

100 Deals associated with AD-010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Disseminated Intravascular Coagulation	Preclinical	CN	Jiangsu Aidea Pharmaceutical Co., Ltd.	-
Inflammation	Preclinical	CN	Jiangsu Aidea Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AD-010

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation